To counteract the rise of multidrug-resistant (MDR) bacteria, Bruker is dedicated to developing new solutions to keep pace. The rapid identification and determination of resistance is vital for clinicians and physicians to provide their patients with the antibiotic that promises rapid, gentle and appropriate treatment, as quickly as possible.